Differential Diagnosis, Prevention, and Treatment of mpox (Monkeypox): A Review for Dermatologists.

The current 2022 mpox (monkeypox) outbreak has been officially recognized as a public health emergency. The mpox clinical symptoms include high fever, fatigue, chills, headache, swollen lymph nodes, muscle aches, and a disseminated painful rash. However, recent cases of mpox have shown a shift in clinical symptoms, with anogenital skin lesions emerging as the predominant feature. Due to the predominant skin manifestations of mpox, dermatologists could be crucial in detecting new mpox cases and educating frontline healthcare professionals about mpox. The mpox virus is continuously evolving and has several variants. Genome sequencing has revealed that the Clade IIb variant is responsible for the 2022 mpox outbreak. Mpox spread may occur through animal-to-human and human-to-human transmission; however, unlike coronavirus disease 2019 (COVID-19), long-range airborne transmission has not been reported. Healthcare professionals are at higher risk of becoming infected since they are usually in close contact with both the patients and potentially contaminated fomites (e.g., examination table, gowns, gloves). Both public and healthcare professionals should take preventive and avoidance measures to limit the spread. Mpox is usually self-limiting and may require only symptomatic treatment; however, it may cause severe complications in special populations such as immunocompromised individuals. For severe infection, clinicians may consider antiviral drugs (off-label), tecovirimat and brincidofovir, originally approved for smallpox treatment. Two smallpox vaccines, ACAM2000® and JYNNEOSTM, can be used as pre-exposure prophylaxis against mpox. JYNNEOSTM, which carries approval for mpox use, has less adverse effect potential than ACAM2000®, and may also be used as post-exposure prophylaxis, preferably within 4 days of exposure.

Does 'Fear of COVID-19' trigger future career anxiety? An empirical investigation considering depression from COVID-19 as a mediator.

BACKGROUND: Due to the outbreak of COVID-19, the mental health of the people all around the world is severely disrupted. AIM: The purpose of this study is to identify whether 'Fear of COVID-19' impacted on future workforces' career anxiety at the first place and whether depression from COVID-19 has any indirect effect on 'Fear of COVID-19' and future workforces' career anxiety. METHOD: Based on three different scales related to 'Fear of COVID-19', depression and career anxiety, a structured questionnaire was developed and the survey data was collected for this study. RESULTS: The empirical result of the study reveals that, due to the outbreak of COVID-19 fear, the future workforce is getting anxious about their future career. Again, depression from COVID-19, caused by 'Fear of COVID-19', as a mediator, has a significant indirect impact on the relationship between 'Fear of COVID-19' and future career anxiety, resulting in a full mediation. This means, due to the outbreak of 'Fear of COVID-19' people are becoming depressed and anxious about their future career which is creating a long-term negative effect on human psychology. CONCLUSION: These research findings will be a major tool for the policymakers, as well as the human resource planning professionals, to sketch plans after COVID-19 pandemic. This study is a novel work combining the concepts of fear and depression with career anxiety in a pandemic situation like COVID-19, and also assists future researchers in many folds.